Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 8/20 | 0.83 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | RHOC | P08134 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | THRB | P10828 | 1/20 | 0.83 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.83 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.75 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.75 |
| ▸ | PDE6D | O43924 | 4/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558520 | 1.00 | HMGCR (0.83) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28552009 | 1.00 | HMGCR (0.83) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13316802 | 0.94 | HMGCR (0.83) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13734511 | 0.93 | HMGCR (0.76) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12507371 | 0.92 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28911057 | 0.92 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12415505 | 0.91 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 0.91 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.91 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL465015 | 0.91 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | disclosed |
| EP-3064272-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | Zannan Scitech Co., Ltd. (CN) | 2016-09-07 | — | — | EP | disclosed |
| EP-2560951-B1 | PRODUCTION OF ATORVASTATIN LOW IN ETHER IMPURITIES | DSM SINOCHEM PHARM NL BV (NL) | 2016-05-25 | — | — | EP | disclosed |
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20130041162-A1 | PRODUCTION OF ATORVASTATIN LOW IN ETHER IMPURITIES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-02-14 | — | — | US | disclosed |
| US-20130041162-A1 | PRODUCTION OF ATORVASTATIN LOW IN ETHER IMPURITIES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-02-14 | — | — | US | disclosed |
| WO-2011131605-A1 | PRODUCTION OF ATORVASTATIN LOW IN ETHER IMPURITIES | DSM IP ASSETS B.V. (NL) | 2011-10-27 | — | — | WO | disclosed |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | HMGCR, CACYBP, SARAF | HMGCR 1/4885SLCO1B1 433/4885ABCB11 2194/4885 |
| US-20130041162-A1 | PRODUCTION OF ATORVASTATIN LOW IN ETHER IMPURITIES | HMGCR, PCSK9, CETP | HMGCR 1/4885SLCO1B1 308/4885ABCB11 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.